Literature DB >> 22400074

No evidence of endometriosis within serous and mucinous tumors of the ovary.

Tadashi Terada1.   

Abstract

Ovarian endometriosis can transform into malignant tumors. The author retrospectively examined HE slides of 112 serous tumors and 75 mucinous tumors for the existence of ovarian endometriosis. When endometriosis is present within the tumors, the term "endometriosis-derived tumor" was applied. When endometriosis is recognized adjacent to the tumor, the term "endometriosis-associated tumor" was used. Of the 112 serous tumors (46 benign, 18 borderline, and 50 malignant), 4 (3.5%) (2 benign and 2 malignant) were endometriosis-associated tumors. None was endometriosis-derived tumor. Of the 75 mucinous tumors (30 benign, 26 borderline, and 19 malignant), 4 (5%) (1 borderline and 3 benign) were endometriosis-associated tumors. No tumors showed endometriosis-derived tumors. The data suggest that endometriosis does not transform into serous and mucous tumors. The author felt the limitation of retrospective survey, because the limited numbers of slides (5 to 15) were obtained from each tumor. The author also felt that endometriosis can be difficult to discern because of degenerative changes and other similar lesions such as fallopian tube, fimbria, inclusion cysts, rete ovarii, paraovarian cyst, and Müllerian ducts remnants. Prospective study using whole ovarian examination is required.

Entities:  

Keywords:  Ovary tumor; endometriosis; endometriosis-derived tumor; ovary mucinous tumor; ovary serous tumor

Mesh:

Year:  2012        PMID: 22400074      PMCID: PMC3294227     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  12 in total

1.  Malignant transformation of ovarian endometriosis.

Authors:  M Nishida; K Watanabe; N Sato; Y Ichikawa
Journal:  Gynecol Obstet Invest       Date:  2000       Impact factor: 2.031

Review 2.  Prevalence of endometriosis in ovarian cancer.

Authors:  H Yoshikawa; H Jimbo; S Okada; K Matsumoto; T Onda; T Yasugi; Y Taketani
Journal:  Gynecol Obstet Invest       Date:  2000       Impact factor: 2.031

Review 3.  The development of malignancy in endometriosis.

Authors:  R E Scully; G S Richardson; J F Barlow
Journal:  Clin Obstet Gynecol       Date:  1966-06       Impact factor: 2.190

4.  Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study.

Authors:  S Ogawa; T Kaku; S Amada; H Kobayashi; T Hirakawa; K Ariyoshi; T Kamura; H Nakano
Journal:  Gynecol Oncol       Date:  2000-05       Impact factor: 5.482

5.  Endometrioid adenocarcinoma of the ovary and endometriosis.

Authors:  P Valenzuela; P Ramos; S Redondo; Y Cabrera; I Alvarez; A Ruiz
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2006-07-17       Impact factor: 2.435

6.  Ovarian endometriosis associated with ovarian cancer and endometrial-endocervical polyps.

Authors:  Antonios Kontoravdis; Areti Augoulea; Irene Lambrinoudaki; George Christodoulakos; Dimitrios Tzortziotis; Ioannis Grammatikakis; Nikolaos Kontoravdis; George Creatsas
Journal:  J Obstet Gynaecol Res       Date:  2007-06       Impact factor: 1.730

7.  Epithelial metaplastic changes in ovarian endometriosis.

Authors:  M Fukunaga; S Ushigome
Journal:  Mod Pathol       Date:  1998-08       Impact factor: 7.842

8.  Endometriosis and ovarian cancer.

Authors:  P Vercellini; F Parazzini; G Bolis; S Carinelli; M Dindelli; N Vendola; L Luchini; P G Crosignani
Journal:  Am J Obstet Gynecol       Date:  1993-07       Impact factor: 8.661

9.  Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women.

Authors:  P D DePriest; E R Banks; D E Powell; J R van Nagell; H H Gallion; L E Puls; J E Hunter; R J Kryscio; M B Royalty
Journal:  Gynecol Oncol       Date:  1992-10       Impact factor: 5.482

10.  Histologic transformation of benign endometriosis to early epithelial ovarian cancer.

Authors:  R Sainz de la Cuesta; J H Eichhorn; L W Rice; A F Fuller; N Nikrui; B A Goff
Journal:  Gynecol Oncol       Date:  1996-02       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.